How much do Wegovy and Zepbound cost without insurance? As of September 2026, the manufacturers' own self-pay channels commonly list Wegovy at $199 to $449 per month depending on dose and fulfillment channel and Zepbound single-dose vials at $349 to $499 per month. Those are the legitimate sources and both prices change, so treat them as dated figures to verify at checkout rather than quotes. Anyone quoting a lower price is usually selling compounded copies, which are not FDA-approved and which we never prescribe.
The pricing question hides a second question that matters more, who reads your labs while you take the drug. That is where the flat $299 membership sits and this page covers both.
- Wegovy self-pay commonly runs $199 to $449 per month and Zepbound vials $349 to $499 per month, as of September 2026, from the manufacturers' own channels.
- Compounded copies quote lower because they skip approval and price by the milligram and they are never prescribed here.
- The flat $299 fee covers the clinician and four Biomarker Audits a year and it never rises with the dose.
- Medication is billed by your pharmacy separately at pharmacy cost with zero markup from GoodLife Health.
The legitimate price ladder
Two manufacturers control the two molecules behind these drugs and both now operate their own self-pay channels because insurance coverage for weight management remains patchy. Novo Nordisk's channel lists Wegovy and Eli Lilly's lists Zepbound, with vials priced below the autoinjectors in most published figures. The Novo Nordisk pricing page and the LillyDirect page carry the current numbers and those pages are the source to verify at checkout, because prices moved several times across 2025 and 2026.
A point worth spelling out, because the same molecule appears under two names. Zepbound and Mounjaro are both tirzepatide. Cash-pay patients are typically routed to Zepbound and Mounjaro fits insurance-covered type 2 diabetes. If a telehealth platform routes a cash-pay patient to Mounjaro, the pricing story is usually worse, not better.
Self-pay prices, as of September 2026
| Wegovy, lowest doses | commonly $199 to $299 per month | NovoCare channels |
|---|---|---|
| Wegovy, higher doses | commonly $299 to $449 per month | NovoCare channels |
| Zepbound vials | commonly $349 to $499 per month | LillyDirect |
| Compounded semaglutide or tirzepatide | commonly $99 to $299 per month | not FDA-approved, never prescribed here |
Why compounded prices are lower
Compounded semaglutide and tirzepatide are copies produced without FDA approval, sold by platforms whose revenue rises with every milligram. The dose menus advertising strengths beyond what any approved product markets are a business artifact, not a clinical schedule. The safety story is documented in the FDA's own alerts on unapproved GLP-1 drugs and on dosing errors with compounded injectable semaglutide.
We name this plainly because the price comparison is where the harm lives. A person comparing $199 compounded against $349 Zepbound is comparing an approved drug with a traceable supply chain against an unapproved copy with none and the honest frame is not which is cheaper but which one a clinician would put their own family on.
The cheapest legitimate Wegovy or Zepbound comes from the manufacturers themselves. Everything cheaper is a copy and the platform selling it earns more as the dose climbs.
What the medication price does not include
A monthly vial does not include anyone reading your labs, anyone titrating the dose against a panel, anyone watching for muscle loss, gallbladder trouble or the thyroid that was never checked before the first injection. In the trial data, semaglutide produced roughly 15 percent average weight loss over 68 weeks in STEP-1 and tirzepatide up to about 22.5 percent in SURMOUNT-1, with individual results varying. Those trials monitored participants. The pharmacy price buys the drug only.
That monitoring is what the membership fee is for. One flat $299 per month covers the clinician relationship and four Biomarker Audits a year, so the dose conversation happens with fasting insulin, HbA1c, ApoB and the whole panel on the table rather than from a scale reading. The fee starts with a single $598 charge covering the first two months together, held at sign-up and charged only once a clinician accepts you into care and from month three it is month to month.


Why the fee and the medicine are separate charges
The separation is deliberate and it is the honest version of the math. If the fee bundled the drug, every price change from Novo or Lilly would force the membership price to move and a dose increase would look like a platform revenue increase. In the unbundled structure, the fee covers the doctor and the pharmacy bills the medicine at its own price. GoodLife Health sets nothing, sees nothing and takes nothing on that transaction. There is no molecule upcharge and no dose upcharge, ever.
Over twelve months the membership arithmetic is $3,588, plus whatever the pharmacy charges at its published price. A person taking Zepbound at a mid dose runs roughly $349 to $499 per month at the pharmacy, so the honest annual total is the fee plus the drug, both stated plainly rather than folded into one number that hides which part moved.
What the monthly math looks like for a real Zepbound patient
Concrete numbers help here, because the sticker prices float and the fee does not. A person on Zepbound vials at a mid dose pays the pharmacy commonly $349 to $499 per month as of September 2026 and pays GoodLife Health $299 per month for the clinician and four Biomarker Audits a year. The honest combined figure is $648 to $798 per month in year one and it is worth saying plainly because any platform that quotes a single bundled number is hiding which line moved when prices change.
The $598 first charge covers the first two months of membership together and is held at sign-up, charged only once a clinician accepts you into care. From month three the fee is month to month and canceling is a settings change rather than a phone call. Over twelve months the membership line is $3,588. The pharmacy line depends on the drug and dose and belongs to the pharmacy, which is the whole point of the unbundled structure. If Lilly's price moves, our fee does not and if your dose drops because your labs say it should, the fee still does not.
The objection about just wanting the drug without the membership
This is a fair position and it deserves a straight answer. If all you want is the medication at the best legitimate price, the manufacturers' own channels sell it direct and you do not need us or any membership to buy it. What you will not get there is anyone reading your labs and that is the entire difference. The trials that established these drugs' safety and efficacy monitored participants with regular labs and clinical oversight. A vial bought alone does not include any of that and the risks that deserve watching, muscle loss, gallbladder trouble, an unchecked thyroid, do not announce themselves.
The membership is the monitoring layer, not a gate in front of the drug. If you already have a clinician who reads your labs quarterly, buy the drug direct and skip us. If you do not, the $299 fee buys the clinician, the four audits and a structure with no profit motive on your dose and the eligibility check costs nothing to see whether a clinician will accept you into care.
How titration works when the fee cannot profit from it
Titration deserves its own section, because it is where the aligned structure shows up in practice. In the trial protocols these drugs titrate upward over weeks to the dose the trial tested and real patients do not always need the full climb. Side effects track dose, muscle loss tracks pace and the lowest effective dose is the safest long-term position. A practice whose revenue rises with each dose increase has a quiet vote in that climb. A practice whose fee is flat does not.
Here the dose is reviewed every 90 days against the repeat Biomarker Audit, with fasting insulin, HbA1c, the lipid panel and the symptom list on the table. If the lowest dose is holding the result, the honest protocol holds the dose. If a higher dose is clinically required, the fee does not change when it is prescribed, because the pharmacy bills the medicine and we take nothing from that transaction. Either direction, the only motive in the room is the panel, which is the version of titration the trial data actually supports.
Who this is not for
If you want the lowest sticker price and nothing else, the manufacturers' channels sell direct and you do not need a membership to buy there. If you want compounded vials, we do not prescribe them and we will not pretend otherwise. And if you are outside the United States, our clinicians are licensed in the fifty states and cannot serve you.
One last thing
The drug prices are public and they move, so verify them at checkout on the manufacturer pages. The number that does not move is the fee, $299 a month for the clinician and the quarterly audit that makes the drug safe to take. A person comparing GLP-1 programs should compare both lines, because the program that bundles them is the program that hides which part is getting more expensive. The eligibility check is free, takes a few minutes and never results in a charge unless a clinician accepts you into care.
Related Guides
- Medical weight loss care
- Why does my GLP-1 dose keep climbing?
- How long can you safely stay on a GLP-1 medication?
- Cardiometabolic Optimization: the definitive guide
References
- Novo Nordisk, Wegovy pricing and NovoCare Pharmacy. novonordisk.com
- Eli Lilly, Zepbound pricing through LillyDirect. lillydirect.lilly.com
- FDA, concerns with unapproved GLP-1 drugs used for weight loss. fda.gov